Recombinant Mouse Artemin (Catalog # 1085-AR) stimulates proliferation in the SH‑SY5Y human neuroblastoma cell line in a dose-dependent manner (orange line). Proliferation elicited by Recombinant Mouse ...read more
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70 °C as supplied.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
6 months, -20 to -70 °C under sterile conditions after reconstitution.
Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied as a 0.2 µm filtered solution in PBS.
Reconstitute at 0.2 mg/mL in sterile PBS.
This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.
Alternate Names for Artemin Antibody [Unconjugated]
Artemin is a member of the Glia Cell-Derived Neurotrophic factor (GDNF) family ligands, which include GDNF, Persephin, Artemin, and Neurturin. GDNF family ligands are distant members of the Transforming Growth Factor beta (TGF‑ beta ) superfamily (1‑4). Similar to other TGF‑ beta family proteins, Artemin is synthesized as a large precursor protein that is cleaved at the dibasic cleavage site (RXXR) to release the carboxy-terminal domain. The carboxy-terminal domain of Artemin contains the characteristic seven conserved cysteine residues necessary for the formation of the cysteine-knot and the single interchain disulfide bond. Biologically active Artemin is a disulfide‑linked homodimer of the carboxy-terminal 113 amino acid residues. Mature mouse Artemin shares 88.5% amino acid sequence similarity with human Artemin. Mature Artemin also shares approximately 40% amino acid sequence identity with the other three members of the GDNF family ligands (5). Bioactivities of all GDNF family ligands are mediated through a receptor complex composed of a high affinity ligand binding component (GFR alpha 1‑GFR alpha 4) and a common signaling component, cRET (receptor tyrosine kinase) (5‑8). Artemin prefers to bind to GFR alpha 3 and activites the GFR alpha 3‑RET. However, in the presence of RET, it can bind to GFR alpha 1 as well (4, 5, 9). Artemin has been shown to promote the survival and growth of various peripheral and central neurons, including sympathetic and dopaminergic neurons. It may also play an important role in the development of sympathetic neurons and several organs (5, 10, 11).
Lin, L-F.H. et al. (1993) Science 260:1130.
Milbrandt, J. et al. (1998) Neuron 20:245.
Kotzbauer, P.T. et al. (1996) Nature 384:467.
Baloh, R.H. et al. (1998) Neuron 21:1291.
Takahashi, M. (2001) Cytokine and Growth Factor Reviews 12:361.
Baloh, R.H. et al. (1997) Neuron 18:793.
Jing, S. et al. (1996) Cell 85:1113.
Jing, S. et al. (1997) J Biol Chem 272:33111.
Nishino, J. et al. (1999) Neuron 23:725.
Enomoto, H. et al. (2001) Development 128:3963.
Andres, R. et al. (2001) Development 128:3685.
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
The concentration calculator allows you to quickly calculate the volume, mass or concentration of your vial. Simply enter your mass, volume, or concentration values for your reagent and the calculator will determine the rest.
Review this Product
Be the first to review our Artemin Antibody [Unconjugated] and receive a gift card or discount.
PRODUCT AVAILABILITY: Update Regarding the Evolving COVID-19 Situation
Bio-Techne appreciates the critical role that you and our products and services play in research efforts to further scientific innovation and discovery. We are continually assessing our manufacturing and supplier capabilities during the COVID-19 situation and are implementing precautionary measures to ensure uninterrupted supply of products and services. Currently, and as we abide by local shelter in place orders across the world, we are fully operational and do not anticipate any material supply disruptions across our Bio-Techne brands and product lines. As the situation evolves, our goal is to utilize preventive measures to reduce the threat that COVID-19 poses to our ability to meet the needs of our customers globally.